Alzheimer’s Disease (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Alzheimer's Disease (AD) Market Outlook

Thelansis’s “Alzheimer's Disease (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alzheimer's Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Alzheimer's Disease (AD) Overview

Alzheimer's disease (AD) is the foremost cause of dementia, accounting for approximately 60% to 80% of all cases of dementia. This condition is a progressive and neurodegenerative ailment characterized by three principal features within the brain: Amyloid plaques, anomalous clumps formed from proteins, remnants of neurons, and fragments of other nerve cells. Neurofibrillary tangles (NETs), knotted bundles of fibers, containing clusters of a protein known as tau, are situated within neurons. The deterioration of connections between neurons leads to memory and learning deficits. Alzheimer's disease exhibits distinctive brain alterations (pathology) distinct from those of other causes of dementia, such as Lewy body disease or Cerebrovascular disease. When these coexisting pathologies are identified during a person's lifetime, it is called mixed dementia. A common initial clinical symptom includes difficulty recollecting recent conversations, names, or events, accompanied by apathy and depression. Alzheimer's disease typically advances gradually through three stages: early, middle, and late. The progression of Alzheimer's disease can be categorized into seven stages:

1. Stage 1: Occurring before the onset of symptoms.
2. Stage 2: Characterized by mild forgetfulness.
3. Stage 3: Marked by noticeable memory difficulties.
4. Stage 4: Involves more than just memory loss.
5. Stage 5: Results in decreased independence.
6. Stage 6: Presents severe symptoms.
7. Stage 7: Features a loss of physical control.

While there is no known cure for Alzheimer's disease, treatments exist to manage its symptoms. These treatments encompass:

• Cholinesterase inhibitors enhance cell-to-cell communication. Commonly prescribed cholinesterase inhibitors encompass Donepezil (Aricept), Galantamine (Razadyne), and Rivastigmine (Exelon).
• Memantine, an NMDA antagonist, is prescribed for moderate to severe Alzheimer's.
• Lecanemab (Leqembi), an FDA-approved medication as of 2023 for individuals with mild Alzheimer's disease and cognitive impairment.

The likelihood of developing Alzheimer's dementia rises with age, affecting 5.3% of those aged 65-74, 13.8% of those aged 75-84, and 34.6% of those aged 85 and above. While Alzheimer's can occur in individuals younger than 65, it is much less common, and its prevalence in this age group remains uncertain.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: